跳到正文
原文
Nature 健康护理主题·· 2026-10-03AI 评分26

老年多重用药患者抗胆碱能负荷:DBI、ACB 与 Duran 量表在初级保健中的比较

Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care

AI 导读

一项纳入 6,550 例 ≥ 65 岁、用药 ≥ 10 种的初级保健患者的多中心横断面研究显示,83.3% 至少被处方一种具抗胆碱能活性药物;DBI 判定 50.2% 为高负荷、44.2% 为中等,而 ACB 量表仅 24.8%、Duran 量表 27.2% 为高风险。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

To evaluate anticholinergic burden in older adults (≥ 65 years) with hyperpolypharmacy (≥ 10 medications) in primary care using the Drug Burden Index (DBI), and to compare the results with those obtained using the Anticholinergic Cognitive Burden (ACB) scale and Duran’s scale. Additionally, factors associated with increased anticholinergic burden were explored. A multicenter cross-sectional study was conducted including 6,550 patients aged ≥ 65 years with hyperpolypharmacy in primary care settings. Sociodemographic, clinical, functional, and pharmacotherapeutic variables were obtained from electronic health records. Anticholinergic burden was assessed using the DBI, ACB, and Duran’s scales. Differences in burden according to patient characteristics were analyzed. Overall, 83.3% of patients were prescribed at least one medication with anticholinergic activity. According to the DBI, 50.2% of patients were classified as having a high anticholinergic burden, 44.2% as moderate burden, and 5.6% as having no risk. In contrast, the ACB scale classified 24.8% of patients as high risk, while Duran’s scale identified 27.2% as high risk. Mean DBI values were significantly higher among women, patients with dementia, individuals with greater cognitive and functional impairment, and those receiving ≥ 15 medications. Lorazepam and tramadol were the most frequently prescribed medications contributing to anticholinergic burden. Anticholinergic burden in older adults with hyperpolypharmacy varies substantially depending on the assessment tool used. The DBI identified a considerably higher burden than the ACB and Duran’s scales, reflecting important methodological differences among instruments. Systematic assessment of anticholinergic burden and regular medication review may help optimize pharmacotherapy and improve medication safety in this vulnerable population.

Abbreviations

AAS:

Anticholinergic Activity Scale

ABC:

Anticholinergic Burden Classification

ACB:

Anticholinergic Cognitive Burden

ADS:

Anticholinergic Drug Scale

ALS:

Anticholinergic Load Scale

ARS:

Anticholinergic Risk Scale

ATC:

Anatomical Therapeutic Chemical

CrAS:

Clinician-Rated Anticholinergic Scale

DBI:

Drug Burden Index

eCAP:

electronic Clinical Station in Primary Care Health Records Database

F:

Female

ICD:

International Classification of Disease

M:

Male

SD:

Standard Deviation

Author information

Authors and Affiliations

  1. Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona, 08028, Spain

    María José Sarria Arroyo, Antonio J. Braza, Montserrat Viñas-Bastart & Pilar Modamio

  2. Delta Primary Care and Community Care Management, Departament de Salut. Generalitat de Catalunya, Institut Català de la Salut, Plaça de l’Aigua, 3, 1a planta, El Prat de Llobregat. Barcelona, 08820, Spain

    Gemma Rodríguez Palomar & Neus Parellada Esquius

Authors

  1. María José Sarria Arroyo
  2. Gemma Rodríguez Palomar
  3. Neus Parellada Esquius
  4. Antonio J. Braza
  5. Montserrat Viñas-Bastart
  6. Pilar Modamio

Corresponding authors

Correspondence to Antonio J. Braza or Pilar Modamio.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Primary Health Care Research Institute Jordi Gol i Gurina (Institut Universitari d’Investigació en Atenció Primària Jordi Gol i Gurina, IDIAPJGol) (reference 21/123-P). The requirement for informed consent was waived by the Clinical Research Ethics Committee of the Primary Health Care Research Institute Jordi Gol i Gurina (IDIAPJGol) (reference 21/123-P), because this was a retrospective cross-sectional study based exclusively on anonymized data.

Consent for publication

All authors agreed to the publication of this manuscript.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendices

ANNEX 1. Population description of anticholinergic scales

Variable

Frequency (no. of patients)

Percentage (%)

DBI Scale

  0 (No risk

303

5.6

  <1 (Moderate)

2410

44.2

  ≥ 1 (High)

2742

50.2

Duran’s Scale

  0 (No risk)

1996

36.6

  1 (Moderate)

1976

36.2

  ≥ 2 (High)

1483

27.2

ACB Scale

  0 (No risk

2878

52.8

  1 (Low)

1004

18.4

  2 (Moderate)

220

4.0

  ≥ 3 (High)

1353

24.8

ANNEX 2. Prescribed medicines whose drugs have anticholinergic activity in DBI scale and anticholinergic load values on the ACB and Duran’s scales

Drug

DBI scale*21

ATC

No. patients (%)

ACB scale**

21

Duran’s scale***

3

Lorazepam

N05BA06

1364 (25.0)

1

0

Tramadol

N02AX02

1068 (19.58)

0

1

Sertraline

N06AB06

721 (13.22)

0

1

Pregabalin

N03AX16

654 (11.99)

0

0

Tamsulosin

G04CA02

646 (11.84)

0

0

Quetiapine

N05AH04

601 (11.02)

3

1

Diazepam

N05BA01

490 (8.98)

1

1

Citalopram

N06AB04

478 (8.76)

0

1

Trazodone

N06AX05

477 (8.74)

1

1

Mirtazapine

N06AX11

431 (7.90)

0

1

Doxazosin

C02CA04

430 (7.88)

0

0

Transdermal Fentanyl

N02AB03

387 (7.09)

1

1

Venlafaxine

N06AX16

343 (6.29)

0

0

Gabapentin

N03AX12

320 (5.87)

0

0

Paroxetine

N06AB05

308 (5.65)

3

1

Amitriptyline

N06AA09

268 (4.91)

3

1

Alprazolam

N05BA12

261 (4.78)

1

0

Clonazepam

N03AE01

259 (4.75)

0

1

Dutasteride + Tamsulosin

G04CA52

190 (3.48)

0

0

Cetirizine

R06AE07

188 (3.45)

0

1

Fluoxetine

N06AB03

142 (2.60)

0

1

Risperidone

N05AX08

132 (2.42)

1

1

Escitalopram

N06AB10

124 (2.27)

0

0

Zolpidem

N05CF02

118 (2.16)

0

0

Solifenacin

G04BD08

117 (2.14)

3

2

Silodosin

G04CA04

100 (1.83)

0

0

Levetiracetam

N03AX14

96 (1.76)

0

0

Clorazepate

N05BA05

93 (1.70)

1

0

Pramipexol

N04BC05

93 (1.70)

0

0

Solifenacin + Tamsulosin

G04CA53

69 (1.26)

0

0

Loratadine

R06AX13

67 (1.23)

0

1

Olanzapine

N05AH03

58 (1.06)

3

1

Oxycodone/Naloxone

N02AA55

58 (1.06)

0

0

Metoclopramide

A03FA01

57 (1.04)

0

0

Intravenous Morphine

N02AA01

57 (1,04)

1

1

Fesoterodine

G04BD11

55 (1.01)

0

0

Clomipramine

N06AA04

52 (0.95)

3

1

Valproic Acid

N03AG01

49 (0.90)

0

0

Carbamazepine

N03AF01

46 (0.84)

2

1

Tolterodine

G04BD07

40 (0.73)

3

2

Haloperidol

N05AD01

39 (0.71)

1

1

Lamotrigine

N03AX09

38 (0.70)

0

0

Codeine Associations

N02AA59

36 (0.66)

2

0

Hydroxyzine

N05BB01

33 (0.60)

3

2

Primidone

N03AA03

30 (0.55)

0

0

Baclofen

M03BX01

26 (0.48)

0

1

Ropinirole

N04BC04

24 (0.44)

0

0

Aripiprazole

N05AX12

22 (0.40)

0

0

Lithium

N05AN01

19 (0.35)

0

1

Oxybutynin

G04BD04

19 (0.35)

3

2

Phenobarbital

N03AA02

18 (0.33)

0

1

Amitriptyline/Medazepam

N06CA92

17 (0.31)

0

0

Dexchlorpheniramine

R06AB52

17 (0.31)

0

2

Phenytoin

N03AB02

17 (0.31)

0

0

Oxcarbazepine

N03AF02

16 (0.29)

2

1

Alfuzosin

G04CA01

15 (0.27)

0

0

Cyclobenzaprine

M03BX08

12 (0.22)

2

1

Metoclopramide/Dimethicone

A03FA

12 (0.22)

0

0

Diazepam/Pyridoxine

N05BA/A11HA

10 (0.18)

0

0

Levocetirizine

R06AE09

10 (0.18)

0

1

Oxycodone

N02AA05

10 (0.18)

0

1

Tizanidine

M03BX02

9 (0.16)

0

2

Imipramine

N06AA02

8 (0.15)

3

2

Terazosin

G04CA03

7 (0.13)

0

0

Loperamide

A07DA03

6 (0.11)

1

1

Nortriptyline

N06AA10

6 (0.11)

3

2

Paliperidone

N05AX13

6 (0.11)

0

0

Trospium

G04BD09

5 (0.09)

0

0

Clonidine

C02AC01

4 (0.07)

0

0

Flurazepam

N05CD01

3 (0.05)

0

0

Hydromorphone

N02AA03

3 (0.05)

0

0

Methocarbamol

M03BA03

3 (0.05)

0

1

Trihexyphenidyl

N04AA01

3 (0.05)

3

2

Asenapine

N05AH05

2 (0.04)

0

0

Doxepin

N06AA12

2 (0.04)

3

2

Prazosin

C02CA01

2 (0.04)

0

0

Dextromethorphan

R05DA09

1 (0.02)

0

0

Dextromethorphan/Diphenhydramine

R05DA20

1 (0.02)

0

2

Diphenhydramine

D04AA32

1 (0.02)

0

2

Disopyramide

C01BA03

1 (0.02)

1

1

Methadone

N07BC02

1 (0.02)

0

1

Methocarbamol/Paracetamol

M03BA53

1 (0.02)

0

1

Perphenazine

N05AB04

1 (0.02)

3

0

Pimozide

N05AG02

1 (0.02)

2

1

Triazolam

N05CD05

1 (0.02)

0

1

Ziprasidone

N05AE04

1 (0.02)

0

0

  1. (*DBI scale: Drug Burden Index: 0 = no risk, < 1 = moderate risk, and ≥ 1 = high risk, **ACB scale: Anticholinergic Cognitive Burden: 0 = no risk, 1 = low risk, 2 = moderate risk, ≥ 3 = high risk. ***Duran’s scale: 0 = no risk, 1 = low risk, ≥ 2 = high risk).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arroyo, M.J.S., Palomar, G.R., Esquius, N.P. et al. Anticholinergic burden in older adults with hyperpolypharmacy: a comparison of the drug burden index, anticholinergic cognitive burden, and duran scales in primary care. Sci Rep (2026). https://doi.org/10.1038/s41598-026-73968-9

Download citation

  • Received: 27 July 2026

  • Accepted: 25 September 2026

  • Published: 03 October 2026

  • DOI: https://doi.org/10.1038/s41598-026-73968-9

Keywords

来源:Nature 健康护理主题 · nature.com